

**Synonym**

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

**Source**

Mouse LY75, His Tag (LY5-M52H5) is expressed from human 293 cells (HEK293). It contains AA Ser 28 - Asp 1667 (Accession # [Q60767-1](#)).

Predicted N-terminus: Ser 28

**Molecular Characterization**

LY75(Ser 28 - Asp 1667) Q60767-1	Poly-his
-------------------------------------	----------

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 190.0 kDa. The protein migrates as 230-260 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

**Endotoxin**

Less than 1.0 EU per µg by the LAL method.

**Purity**

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

**Formulation**

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

**Reconstitution**

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

**Storage**


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

**SDS-PAGE**



Mouse LY75, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

**SEC-MALS**



The purity of Mouse LY75, His Tag (Cat. No. LY5-M52H5) is more than 90% and the molecular weight of this protein is around 210-255 kDa verified by SEC-MALS.

[Report](#)

**Background**

lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.

### Clinical and Translational Updates

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.